Key Laboratory of Pharmaceutical Quality Control of Hebei Province, College of Pharmaceutical Sciences, Hebei University, Baoding, Hebei, 071002, China.
State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China.
Eur J Med Chem. 2023 Apr 5;252:115303. doi: 10.1016/j.ejmech.2023.115303. Epub 2023 Mar 24.
Both topoisomerase II (Topo II) and histone deacetylase (HDAC) are important therapeutic targets for cancer. In this study, two series of novel compounds containing pyrimido[5,4-b]indole and pyrazolo[3,4-d]pyrimidine motifs were designed and synthesized as dual Topo II/HDAC inhibitors. MTT assay indicated that all the compounds displayed potential antiproliferative activity against three cancer cell lines (MGC-803, MCF-7 and U937) and low cytotoxicity on normal cell line (3T3). In the enzyme activity inhibition experiments, compounds 7d and 8d exhibited excellent dual inhibitory activities against Topo II and HDAC. Cleavage reaction assay showed that 7d was a Topo II poison, which was consistent with the docking results. Further experimental results revealed that compounds 7d and 8d could promote apoptosis and significantly inhibit the migration in MCF-7 cells. Molecular docking showed that compounds 7d and 8d bind Topo II and HDAC at the active sites. Molecular dynamics simulation showed that 7d can stably bind to Topo II and HDAC.
拓扑异构酶 II(Topo II)和组蛋白去乙酰化酶(HDAC)都是癌症的重要治疗靶点。在这项研究中,设计并合成了两个系列含有嘧啶并[5,4-b]吲哚和吡唑并[3,4-d]嘧啶结构的新型化合物,作为双 Topo II/HDAC 抑制剂。MTT 法实验表明,所有化合物对三种癌细胞系(MGC-803、MCF-7 和 U937)均表现出潜在的增殖抑制活性,对正常细胞系(3T3)的细胞毒性较低。在酶活性抑制实验中,化合物 7d 和 8d 对 Topo II 和 HDAC 表现出优异的双重抑制活性。裂解反应实验表明,7d 是一种 Topo II 型毒物,这与对接结果一致。进一步的实验结果表明,化合物 7d 和 8d 能够促进 MCF-7 细胞的凋亡并显著抑制其迁移。分子对接显示,化合物 7d 和 8d 可以结合 Topo II 和 HDAC 的活性部位。分子动力学模拟表明,7d 可以稳定地结合 Topo II 和 HDAC。